Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling

Biofilms and infectious process may alter free antimicrobial concentrations at the site of infection. Tobramycin (TOB), an aminoglycoside used to treat lung infections caused by Pseudomonas aeruginosa, binds to alginate present in biofilm extracellular matrix increasing its minimum inhibitory concen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias, Bruna Bernar, Carreño, Fernando, Helfer, Victória Etges, Garzella, Priscila Martini Bernardi, de Lima, Daiane Maria Fonseca, Barreto, Fabiano, de Araújo, Bibiana Verlindo, Dalla Costa, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228144/
https://www.ncbi.nlm.nih.gov/pubmed/35745809
http://dx.doi.org/10.3390/pharmaceutics14061237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228144/
https://www.ncbi.nlm.nih.gov/pubmed/35745809
http://dx.doi.org/10.3390/pharmaceutics14061237

Ejemplares similares